Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Objective: To assess the safety and tolerability and to explore the preliminary efficacy of intermittent intraputamenal monthly infusions of CDNF in subjects with advanced idiopathic…The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses
Objective: We present the results of several post hoc analyses of the LEAP-study. Background: Among patients with Parkinson’s disease who were evaluated in the LEAP-study…Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations
Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…Cardiovascular Fitness, Plasma Biomarkers and Dopaminergic Denervation in Parkinson’s Disease
Objective: To examine the relationship between cardiovascular (CV) fitness, plasma biomarkers associated with PD progression and/or exercise and dopaminergic denervation, measured by I-123-Ioflupane single photon…A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)
Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…Helicobacter pylori eradication in Parkinson’s disease: A double-blind randomized placebo-controlled study
Objective: To evaluate the effects of Helicobacter pylori eradication on PD symptoms. Background: Globally, H. pylori infection remains a common problem. Cross-sectional studies in Parkinson's disease (PD)…Opicapone study in daily clinical practice. OPRA study
Objective: Improvement of off time and increase of ON time without dyskinesias at 6 months compared to the baseline situation. Secondary Endpoints: Determine the rate…Opicapone in Parkinson’s disease – a centre’s real-life experience
Objective: To evaluate the therapeutic benefits, safety and tolerability of opicapone in a centre’s clinical practice. Background: Opicapone is a recent treatment for motor fluctuations…Complex patterns of dyskinesias in patients chronically treated with enterally administered levodopa/carbidopa gel
Objective: Report cases of biphasic dyskinesia in patients with advanced Parkinson's disease. Background: Diphasic dyskinesia (DD) is a complex pattern of levodopa (LD) induced diskynesia…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 149
- Next Page »